Non-invasive cardiac imaging has explored enormous advances in the last few decades.In particular,hybrid imaging represents the fusion of information from multiple imaging modalities,allowing to provide a more compreh...Non-invasive cardiac imaging has explored enormous advances in the last few decades.In particular,hybrid imaging represents the fusion of information from multiple imaging modalities,allowing to provide a more comprehensive dataset compared to traditional imaging techniques in patients with cardiovascular diseases.The complementary anatomical,functional and molecular information provided by hybrid systems are able to simplify the evaluation procedure of various pathologies in a routine clinical setting.The diagnostic capability of hybrid imaging modalities can be further enhanced by introducing novel and specific imaging biomarkers.The aim of this review is to cover the most recent advancements in radiotracers development for SPECT/CT,PET/CT,and PET/MRI for cardiovascular diseases.展开更多
背景与目的:示踪剂是前哨淋巴结活检的关键,传统荧光示踪剂无法靶向前哨淋巴结且荧光强度弱。探寻一种近红外荧光强度更大、穿透力更好的新型增强近红外荧光示踪剂聚甲川菁染料分子Cy754,并将其与利妥昔单抗(rituximab,Rit)结合形成新...背景与目的:示踪剂是前哨淋巴结活检的关键,传统荧光示踪剂无法靶向前哨淋巴结且荧光强度弱。探寻一种近红外荧光强度更大、穿透力更好的新型增强近红外荧光示踪剂聚甲川菁染料分子Cy754,并将其与利妥昔单抗(rituximab,Rit)结合形成新型近红外荧光靶向示踪剂Cy754-Rit。方法:化学合成新型增强近红外荧光示踪剂Cy754,检测其相对分子质量、激发光谱、吸收光谱等,将其与Rit进行直接偶联。测定Cy754-Rit标记率,检测新型示踪剂中单抗分子完整性和免疫活性。采用近红外成像仪将Cy754-Rit与吲哚菁绿(indocyanine green,ICG)-Rit的荧光强度作比较,检测其安全限度,通过前哨淋巴结动物模型验证其前哨淋巴结的定位特性,并与Cy754、ICG-Rit、核素进行对比。结果:Cy754的相对分子质量为818,激发波长为740 nm,发射波长为760 nm。直接偶联并纯化的Cy754-Rit保持了分子完整性和免疫活性。Rit上的Cy754标记率为100%。Cy754-Rit的荧光强度优于ICG-Rit(3.08×1010 vs 6.56×108)。透析纯化后的新型增强靶向示踪剂中未检测到细菌和热原。实验动物局部注射,观察2周后,局部及全身无红肿也无皮疹,无死亡。Rit与Cy754偶联的最佳的物质的量比为1∶80。Cy754-Rit能够准确地定位前哨淋巴结,其定位特性与核素相似,但发射荧光穿透力优于ICGRit(14.3 mm vs 13.2 mm)。结论:Cy754-Rit的制备工艺简便、高效、无放射性,其荧光强度较传统荧光靶向示踪剂明显增强。经动物模型局部注射能够准确地定位到前哨淋巴结,显像清晰稳定,穿透力好,但仍需临床试验进行相关验证。展开更多
文摘Non-invasive cardiac imaging has explored enormous advances in the last few decades.In particular,hybrid imaging represents the fusion of information from multiple imaging modalities,allowing to provide a more comprehensive dataset compared to traditional imaging techniques in patients with cardiovascular diseases.The complementary anatomical,functional and molecular information provided by hybrid systems are able to simplify the evaluation procedure of various pathologies in a routine clinical setting.The diagnostic capability of hybrid imaging modalities can be further enhanced by introducing novel and specific imaging biomarkers.The aim of this review is to cover the most recent advancements in radiotracers development for SPECT/CT,PET/CT,and PET/MRI for cardiovascular diseases.
文摘背景与目的:示踪剂是前哨淋巴结活检的关键,传统荧光示踪剂无法靶向前哨淋巴结且荧光强度弱。探寻一种近红外荧光强度更大、穿透力更好的新型增强近红外荧光示踪剂聚甲川菁染料分子Cy754,并将其与利妥昔单抗(rituximab,Rit)结合形成新型近红外荧光靶向示踪剂Cy754-Rit。方法:化学合成新型增强近红外荧光示踪剂Cy754,检测其相对分子质量、激发光谱、吸收光谱等,将其与Rit进行直接偶联。测定Cy754-Rit标记率,检测新型示踪剂中单抗分子完整性和免疫活性。采用近红外成像仪将Cy754-Rit与吲哚菁绿(indocyanine green,ICG)-Rit的荧光强度作比较,检测其安全限度,通过前哨淋巴结动物模型验证其前哨淋巴结的定位特性,并与Cy754、ICG-Rit、核素进行对比。结果:Cy754的相对分子质量为818,激发波长为740 nm,发射波长为760 nm。直接偶联并纯化的Cy754-Rit保持了分子完整性和免疫活性。Rit上的Cy754标记率为100%。Cy754-Rit的荧光强度优于ICG-Rit(3.08×1010 vs 6.56×108)。透析纯化后的新型增强靶向示踪剂中未检测到细菌和热原。实验动物局部注射,观察2周后,局部及全身无红肿也无皮疹,无死亡。Rit与Cy754偶联的最佳的物质的量比为1∶80。Cy754-Rit能够准确地定位前哨淋巴结,其定位特性与核素相似,但发射荧光穿透力优于ICGRit(14.3 mm vs 13.2 mm)。结论:Cy754-Rit的制备工艺简便、高效、无放射性,其荧光强度较传统荧光靶向示踪剂明显增强。经动物模型局部注射能够准确地定位到前哨淋巴结,显像清晰稳定,穿透力好,但仍需临床试验进行相关验证。
